1. Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation.Curreli, F., S. Ahmed, S.M. Benedict Victor, I.R. Iusupov, D.S. Belov, P.O. Markov, A.V. Kurkin, A. Altieri, and A.K. Debnath. Journal of Medicinal Chemistry, 2020. 63(4): p. 1724-1749. PMID[32031803].
[PubMed]. HIV_02_2020.
2. Design, Synthesis and Biological Evaluation of HIV-1 Protease Inhibitors with Morpholine Derivatives as P2 Ligands in Combination with Cyclopropyl as P1' Ligand. Dou, Y., M. Zhu, B. Dong, J.X. Wang, G.N. Zhang, F. Zhang, and Y.C. Wang. Bioorganic & Medicinal Chemistry Letters, 2020. 30(7): 127019. PMID[32057582].
[PubMed]. HIV_02_2020.
3. Discovery of Dihydroxyindole-2-carboxylic acid Derivatives as Dual Allosteric HIV-1 Integrase and Reverse transcriptase Associated Ribonuclease H Inhibitors. Esposito, F., M. Sechi, N. Pala, A. Sanna, P.C. Koneru, M. Kvaratskhelia, L. Naesens, A. Corona, N. Grandi, R. di Santo, V.M. D'Amore, F.S. Di Leva, E. Novellino, S. Cosconati, and E. Tramontano. Antiviral Research, 2020. 174: 104671. PMID[31812637].
[PubMed]. HIV_02_2020.
4. Design, Synthesis and Biological Evaluation of Quinoxaline Compounds as anti-HIV Agents Targeting Reverse transcriptase Enzyme. Fabian, L., M. Taverna Porro, N. Gomez, M. Salvatori, G. Turk, D. Estrin, and A. Moglioni. European Journal of Medicinal Chemistry, 2020. 188: 111987. PMID[31893549].
[PubMed]. HIV_02_2020.
5. Discovery and Characterization of Fluorine-substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.Kang, D., F.X. Ruiz, D. Feng, A. Pilch, T. Zhao, F. Wei, Z. Wang, Y. Sun, Z. Fang, E. De Clercq, C. Pannecouque, E. Arnold, X. Liu, and P. Zhan. Journal of Medicinal Chemistry, 2020. 63(3): p. 1298-1312. PMID[31935327].
[PubMed]. HIV_02_2020.
6. Design, Synthesis and Biological Evaluation of Novel 2-(5-Aryl-1H-imidazol-1-yl) Derivatives as Potential Inhibitors of the HIV-1 Vpu and Host BST-2 Protein Interaction. Rashamuse, T.J., Z. Njengele, E.M. Coyanis, Y. Sayed, S. Mosebi, and M.L. Bode. European Journal of Medicinal Chemistry, 2020. 190: 112111. PMID[32058240].
[PubMed]. HIV_02_2020.
7. Daphnane Diterpenoids from Trigonostemon lii and Inhibition Activities against HIV-1. Tan, C.J., S.F. Li, N. Huang, Y. Zhang, Y.T. Di, Y.T. Zheng, and X.J. Hao. Natural Products and Bioprospecting, 2020. 10(1): p. 37-44. PMID[32048186].
[PubMed]. HIV_02_2020.
Patent Citations
8. Inhibitors to Target HIV-1 NEF-CD80/CD86 Interactions for Therapeutic Intervention. Ambala, S., S. Jameel, A. Karumbati, S. Mayor, G. Munagala, A. Munjal, S. Rath, T. Saiyed, S. Sharma, P.P. Singh, R.A. Vishwakarma, and K.R. Yempalla. Patent. 2020. 2019-050594 2020035880: 122pp.
[Patent]. HIV_02_2020.
9. Inhibitors of Human Immunodeficiency Virus Replication. Belema, M. and M. Patel. Patent. 2020. 2019-056727 2020031112: 35pp.
[Patent]. HIV_02_2020.
10. Inhibitors of Histone Deacetylase Useful for the Treatment or Prevention of HIV Infection. Clausen, D.J., J. Kelly, H. Kim, J. Kozlowski, J. Liu, and W. Yu. Patent. 2020. 2019-043543 2020028150: 202pp.
[Patent]. HIV_02_2020.
11. Compounds Useful in HIV Therapy. De La Rosa, M.A., J.F. Miller, B.N. Naidu, L. Suwandi, D. Temelkoff, and E.J. Velthuisen. Patent. 2020. 2019-056761 2020031131: 95pp.
[Patent]. HIV_02_2020.